The connection between AlkB homologs and oncometabolites was discovered when some IDH-mutant glioma patients responded to a combination of alkylating agent chemotherapy, and this outcome was linked to the inhibition of the AlkB human homologs, ALKBH repair proteins, by the oncometabolite 2HG [26,62]. Here, IDH2 is linked to central nervous system cancer.